OMARINI, Claudia
OMARINI, Claudia
Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature.
2019-01-01 D'Onofrio, Raffaella; Piacentini, Federico; Combi, Francesca; Omarini, Claudia; Luca, Moscetti; Antonella, Drago; Andreotti, Alessia; Rovesti, Giulia; Enza, Palma; Anna, Gambini; Papi, Simona; Tazzioli, Giovanni
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC).
2019-01-01 Omarini, Claudia; Piacentini, Federico; Frassoldati, Antonio; Musolino, Antonino; Dominici, Massimo; Moscetti on behalf of GOIRC, Luca
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!
2020-01-01 Omarini, C.; Maur, M.; Luppi, G.; Narni, F.; Luppi, M.; Dominici, M.; Longo, G.; Piacentini, F.
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients.
2018-01-01 Pozzi, S.; Belletti, L.; Cortesi, L.; Moscetti, L.; Omarini, C.; Piacentini, F.; Toss, A.; Caputo, Francesco; Greco, S.; Isca, C.; Napolitano, M.; Tarantino, V.; Malinverni, C.; Checchi, Eleonora; Mascia, Maria Teresa; Cascinu, S
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
2021-01-01 Isca, Chrystel; Piacentini, Federico; Mastrolia, Ilenia; Masciale, Valentina; Caggia, Federica; Toss, Angela; Piombino, Claudia; Moscetti, Luca; Barbolini, Monica; Maur, Michela; Dominici, Massimo; Omarini, Claudia
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors.
2016-01-01 Omarini, Claudia; Caprera, Cecilia; Manfredini, Samantha; Caggia, Federica; Guaitoli, Giorgia; Filieri, Maria Elisabetta; Moscetti, Luca; Bettelli, Stefania Raffaella; Kaleci, Shaniko; Cascinu, Stefano; Piacentini, Federico
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients.
2018-01-01 Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Caggia, F; Guaitoli, G; Moscetti, L; Toss, A; Cortesi, L; Kaleci, S; Maiorana, A; Cascinu, S; Conte, Pf; Piacentini, F
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer
2020-01-01 Isca, Chrystel; Omarini, Claudia; Cortesi, Giulia; Moscetti, Luca; Barbolini, Monica; Dominici, Massimo; Piacentini, Federico
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center.
2019-01-01 Barbolini, M; Omarini, C; Viola, L; Isca, C; Marchi, I; Caggia, F; Barbieri, E; Toss, A; Cortesi, L; Dominici, M; Piacentini, F.
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
2020-01-01 Omarini, C.; Piacentini, F.; Sperduti, I.; Barbolini, M.; Isca, C.; Toss, A.; Cortesi, L.; Barbieri, E.; Dominici, M.; Moscetti, L.
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status
2017-01-01 Omarini, Claudia; Kaleci, Shaniko; Guaitoli, Giorgia; Bettelli, Stefania Raffaella; Cecilia, Caprera; Manfredini, Samantha; Caggia, Federica; Baschieri, MARIA CRISTINA; Luca, Moscetti; Maiorana, Antonino; Cascinu, Stefano; Piacentini, Federico
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status.
2017-01-01 Omarini, C; Kaleci, S; Guaitoli, G; Bettelli, S; Caprera, Cecilia; Manfredini, S; Caggia, F; Baschieri, Cristina; Moscetti, Luca; Maiorana, A; Cascinu, S; Piacentini, F
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.
2019-01-01 Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting
2020-01-01 Pizzuti, L; Krasniqi, E; Barchiesi, G; Della Giulia, M; Izzo, F; Sanguineti, G; Marchetti, P; Mazzotta, M; Giusti, R; Botticelli, A; Gamucci, T; Natoli, C; Grassadonia, A; Tinari, N; Iezzi, L; Tomao, S; Tomao, F; Tonini, G; Santini, D; Astone, A; Michelotti, A; De Angelis, C; Mentuccia, L; Vaccaro, A; Magnolfi, E; Gelibter, A; Magri, V; Cortesi, E; D'Onofrio, L; Cassano, A; Rossi, E; Cazzaniga, M; Moscetti, L; Omarini, C; Piacentini, F; Fabbri, Ma; Scinto, Af; Corsi, D; Carbognin, L; Bria, E; La Verde, N; Samaritani, R; Garufi, C; Barni, S; Mirabelli, R; Sarmiento, R; Veltri, E; D'Auria, G; Paris, I; Giotta, F; Lorusso, V; Cardillo, F; Landucci, E; Mauri, M; Ficorella, C; Roselli, M; Adamo, V; Ricciardi, Grr; Russo, A; Berardi, R; Pistelli, M; Fiorio, E; Cannita, K; Sini, V; D'Ostilio, N; Foglietta, J; Greco, F; Zamagni, C; Garrone, O; Di Cocco, B; Baldini, E; Livi, L; Desideri, I; Meattini, I; Sarobba, G; Del Medico, P; De Tursi, M; Generali, D; De Maria, R; Risi, E; Ciliberto, G; Sperduti, I; Villa, A; Barba, M; Di Leo, A; Vici, P.
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
2021-01-01 Del Re, M; Omarini, C; Diodati, L; Palleschi, M; Meattini, I; Crucitta, S; Lorenzini, G; Isca, C; Fontana, A; Livi, L; Piacentini, F; Fogli, S; De Giorgi, U; Danesi, R.
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better?
2018-01-01 Toss, A.; Venturelli, M.; Sperduti, I.; Isca, C.; Barbieri, E.; Piacentini, F.; Omarini, C.; Cortesi, L; Cascinu, Stefano; Moscetti, L.
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial
2019-01-01 Omarini, C; Sperduti, I; Barbolini, M; Isca, C; Bocconi, Alessandro; Toss, A; Cortesi, L; Barbieri, E; Piacentini, F; Cascinu, S; Moscetti, L
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials.
2019-01-01 Omarini, Claudia; Piacentini, Federico; Sperduti, Isabella; Barbolini, Monica; Isca, Chrystel; Nasso, Cecilia; Toss, Angela; D'Onofrio, Raffaella; Cortesi, Laura; Barbieri, Elena; Cascinu, Stefano; Moscetti, Luca
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences.
2018-01-01 Venturelli, M.; Toss, A.; Piacentini, F.; Artuso, L.; Bernardis, I.; Parenti, S.; Tenedini, E.; Omarini, C.; Moscetti., 1; Cascinu, S.; Tagliafico, E.; Cortesi, L.
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better?
2018-01-01 Toss, A; Venturelli, M; Sperduti, I; Isca, C; Molinaro, E; Barbieri, E; Piacentini, F; Omarini, C; Cortesi, L; Cascinu, S; Moscetti,
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. | 1-gen-2019 | D'Onofrio, Raffaella; Piacentini, Federico; Combi, Francesca; Omarini, Claudia; Luca, Moscetti; Antonella, Drago; Andreotti, Alessia; Rovesti, Giulia; Enza, Palma; Anna, Gambini; Papi, Simona; Tazzioli, Giovanni | |
| Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). | 1-gen-2019 | Omarini, Claudia; Piacentini, Federico; Frassoldati, Antonio; Musolino, Antonino; Dominici, Massimo; Moscetti on behalf of GOIRC, Luca | |
| Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! | 1-gen-2020 | Omarini, C.; Maur, M.; Luppi, G.; Narni, F.; Luppi, M.; Dominici, M.; Longo, G.; Piacentini, F. | |
| Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. | 1-gen-2018 | Pozzi, S.; Belletti, L.; Cortesi, L.; Moscetti, L.; Omarini, C.; Piacentini, F.; Toss, A.; Caputo, Francesco; Greco, S.; Isca, C.; Napolitano, M.; Tarantino, V.; Malinverni, C.; Checchi, Eleonora; Mascia, Maria Teresa; Cascinu, S | |
| Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature | 1-gen-2021 | Isca, Chrystel; Piacentini, Federico; Mastrolia, Ilenia; Masciale, Valentina; Caggia, Federica; Toss, Angela; Piombino, Claudia; Moscetti, Luca; Barbolini, Monica; Maur, Michela; Dominici, Massimo; Omarini, Claudia | |
| Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. | 1-gen-2016 | Omarini, Claudia; Caprera, Cecilia; Manfredini, Samantha; Caggia, Federica; Guaitoli, Giorgia; Filieri, Maria Elisabetta; Moscetti, Luca; Bettelli, Stefania Raffaella; Kaleci, Shaniko; Cascinu, Stefano; Piacentini, Federico | |
| Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. | 1-gen-2018 | Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Caggia, F; Guaitoli, G; Moscetti, L; Toss, A; Cortesi, L; Kaleci, S; Maiorana, A; Cascinu, S; Conte, Pf; Piacentini, F | |
| Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer | 1-gen-2020 | Isca, Chrystel; Omarini, Claudia; Cortesi, Giulia; Moscetti, Luca; Barbolini, Monica; Dominici, Massimo; Piacentini, Federico | |
| Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. | 1-gen-2019 | Barbolini, M; Omarini, C; Viola, L; Isca, C; Marchi, I; Caggia, F; Barbieri, E; Toss, A; Cortesi, L; Dominici, M; Piacentini, F. | |
| Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials | 1-gen-2020 | Omarini, C.; Piacentini, F.; Sperduti, I.; Barbolini, M.; Isca, C.; Toss, A.; Cortesi, L.; Barbieri, E.; Dominici, M.; Moscetti, L. | |
| Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status | 1-gen-2017 | Omarini, Claudia; Kaleci, Shaniko; Guaitoli, Giorgia; Bettelli, Stefania Raffaella; Cecilia, Caprera; Manfredini, Samantha; Caggia, Federica; Baschieri, MARIA CRISTINA; Luca, Moscetti; Maiorana, Antonino; Cascinu, Stefano; Piacentini, Federico | |
| Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. | 1-gen-2017 | Omarini, C; Kaleci, S; Guaitoli, G; Bettelli, S; Caprera, Cecilia; Manfredini, S; Caggia, F; Baschieri, Cristina; Moscetti, Luca; Maiorana, A; Cascinu, S; Piacentini, F | |
| Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. | 1-gen-2019 | Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F | |
| Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting | 1-gen-2020 | Pizzuti, L; Krasniqi, E; Barchiesi, G; Della Giulia, M; Izzo, F; Sanguineti, G; Marchetti, P; Mazzotta, M; Giusti, R; Botticelli, A; Gamucci, T; Natoli, C; Grassadonia, A; Tinari, N; Iezzi, L; Tomao, S; Tomao, F; Tonini, G; Santini, D; Astone, A; Michelotti, A; De Angelis, C; Mentuccia, L; Vaccaro, A; Magnolfi, E; Gelibter, A; Magri, V; Cortesi, E; D'Onofrio, L; Cassano, A; Rossi, E; Cazzaniga, M; Moscetti, L; Omarini, C; Piacentini, F; Fabbri, Ma; Scinto, Af; Corsi, D; Carbognin, L; Bria, E; La Verde, N; Samaritani, R; Garufi, C; Barni, S; Mirabelli, R; Sarmiento, R; Veltri, E; D'Auria, G; Paris, I; Giotta, F; Lorusso, V; Cardillo, F; Landucci, E; Mauri, M; Ficorella, C; Roselli, M; Adamo, V; Ricciardi, Grr; Russo, A; Berardi, R; Pistelli, M; Fiorio, E; Cannita, K; Sini, V; D'Ostilio, N; Foglietta, J; Greco, F; Zamagni, C; Garrone, O; Di Cocco, B; Baldini, E; Livi, L; Desideri, I; Meattini, I; Sarobba, G; Del Medico, P; De Tursi, M; Generali, D; De Maria, R; Risi, E; Ciliberto, G; Sperduti, I; Villa, A; Barba, M; Di Leo, A; Vici, P. | |
| Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. | 1-gen-2021 | Del Re, M; Omarini, C; Diodati, L; Palleschi, M; Meattini, I; Crucitta, S; Lorenzini, G; Isca, C; Fontana, A; Livi, L; Piacentini, F; Fogli, S; De Giorgi, U; Danesi, R. | |
| Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? | 1-gen-2018 | Toss, A.; Venturelli, M.; Sperduti, I.; Isca, C.; Barbieri, E.; Piacentini, F.; Omarini, C.; Cortesi, L; Cascinu, Stefano; Moscetti, L. | |
| Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial | 1-gen-2019 | Omarini, C; Sperduti, I; Barbolini, M; Isca, C; Bocconi, Alessandro; Toss, A; Cortesi, L; Barbieri, E; Piacentini, F; Cascinu, S; Moscetti, L | |
| Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. | 1-gen-2019 | Omarini, Claudia; Piacentini, Federico; Sperduti, Isabella; Barbolini, Monica; Isca, Chrystel; Nasso, Cecilia; Toss, Angela; D'Onofrio, Raffaella; Cortesi, Laura; Barbieri, Elena; Cascinu, Stefano; Moscetti, Luca | |
| ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. | 1-gen-2018 | Venturelli, M.; Toss, A.; Piacentini, F.; Artuso, L.; Bernardis, I.; Parenti, S.; Tenedini, E.; Omarini, C.; Moscetti., 1; Cascinu, S.; Tagliafico, E.; Cortesi, L. | |
| First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? | 1-gen-2018 | Toss, A; Venturelli, M; Sperduti, I; Isca, C; Molinaro, E; Barbieri, E; Piacentini, F; Omarini, C; Cortesi, L; Cascinu, S; Moscetti, |